Exenatide (Bydureon®)

Assessment Status Rapid review complete
Drug Exenatide
Brand Bydureon®
Indication For the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.
Assessment Process
Rapid review commissioned 31/05/2011
Rapid review completed 09/06/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended